Daiichi Sankyo, Inc. (4568.t) CEO John Gargiulo Elected as National Pharmaceutical Council's Chairman of the Board
11/5/2012 10:05:14 AM
WASHINGTON, Nov. 2, 2012 -- The National Pharmaceutical Council (NPC) today announced that John Gargiulo, President & CEO, Daiichi Sankyo, Inc., has been elected Chairman of its Board of Directors for 2012-13. Mr. Gargiulo has served on NPC's Board since 2007, most recently as Vice Chair.
"For many years, John has been committed to fostering NPC's growth as a leading health care policy research organization," said NPC President Dan Leonard. "We're looking forward to his leadership as chairman. He brings a strong track record of accomplishment from Daiichi Sankyo and a keen understanding of the issues facing our industry and actionable ideas for change."
"Now more than ever, we need to demonstrate that pharmaceuticals not only successfully treat and cure disease, but that they can help manage the costs of health care over time. By managing chronic and preventable diseases with medicines that have proven to work, we can reduce hospitalizations, and most of all, help people lead longer and healthier lives," said Mr. Gargiulo. "As chairman, I'm looking forward to leading NPC as it continues to move forward on issues related to balancing the needs of patients with the population, the value of pharmaceuticals, and the use of real-world evidence."
Mr. Gargiulo has more than 25 years of pharmaceutical industry experience. He has been instrumental in building and shaping the company's U.S. commercial operations, particularly its cardiovascular business, since its inception in 1996. He has touched nearly every aspect of business operations including Marketing, Managed Markets and New Product Planning. In the U.S. Daiichi Sankyo markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome and metastatic melanoma.
The NPC Board also elected Jeff Huth, Senior Vice President, Managed Markets, Boehringer Ingelheim Pharmaceuticals, Inc., to serve as its Vice Chair, and Anne Whitaker, President, North America Pharmaceuticals, Sanofi, as Treasurer. Rich Fante, President, U.S. Business & Regional Vice President, Americas, AstraZeneca, is the outgoing chair and will remain active on NPC's Board.
"Under Rich's leadership, NPC took a leap forward as an organization, becoming a more powerful voice in educating key health care stakeholders about the development and application of comparative effectiveness research and other data important to improving health outcomes," said Mr. Leonard.
About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.
SOURCE National Pharmaceutical Council